OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Makes New Investment in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 44,600 shares of the company's stock, valued at approximately $855,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.06% of Viridian Therapeutics at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Voya Investment Management LLC boosted its stake in Viridian Therapeutics by 5.1% in the 4th quarter. Voya Investment Management LLC now owns 21,397 shares of the company's stock worth $410,000 after buying an additional 1,038 shares during the last quarter. Tudor Investment Corp ET AL raised its holdings in shares of Viridian Therapeutics by 3.0% during the 4th quarter. Tudor Investment Corp ET AL now owns 38,367 shares of the company's stock valued at $735,000 after buying an additional 1,106 shares during the period. R Squared Ltd purchased a new stake in Viridian Therapeutics during the 4th quarter worth approximately $26,000. Summit Investment Advisors Inc. increased its holdings in Viridian Therapeutics by 24.7% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock worth $147,000 after purchasing an additional 1,516 shares during the last quarter. Finally, AlphaQuest LLC increased its holdings in shares of Viridian Therapeutics by 119.0% in the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock valued at $54,000 after acquiring an additional 1,519 shares during the last quarter.

Analysts Set New Price Targets

A number of research analysts recently issued reports on VRDN shares. JMP Securities reduced their price objective on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research report on Wednesday, May 7th. HC Wainwright reiterated a "buy" rating and set a $34.00 price target on shares of Viridian Therapeutics in a research report on Wednesday, April 23rd. Royal Bank of Canada dropped their price objective on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Needham & Company LLC cut their target price on Viridian Therapeutics from $38.00 to $36.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Finally, The Goldman Sachs Group lowered their target price on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $36.70.

Viridian Therapeutics Trading Down 1.6%

Shares of NASDAQ:VRDN traded down $0.21 during midday trading on Monday, hitting $12.73. The company had a trading volume of 127,079 shares, compared to its average volume of 1,191,630. Viridian Therapeutics, Inc. has a 12 month low of $9.90 and a 12 month high of $27.20. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.04 billion, a price-to-earnings ratio of -2.94 and a beta of 0.57. The firm has a fifty day simple moving average of $13.41 and a 200 day simple moving average of $17.10.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($0.95) by $0.08. The company had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.16 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The company's revenue was up .0% compared to the same quarter last year. On average, analysts predict that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.